Results 31 to 40 of about 2,386,530 (346)

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +2 more sources

Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy via Immune Activation and Checkpoint Inhibition.

ACS Nano, 2020
Natural, extracellular membrane vesicles secreted by Gram-negative bacteria, outer membrane vesicles (OMVs), contain numerous pathogen-associated molecular patterns which can activate systemic immune responses.
Yao Li, Ruifang Zhao, Keman Cheng, Kaiyue Zhang, Yazhou Wang, Yinlong Zhang, Yujing Li, Guangna Liu, Junchao Xu, Jiaqi Xu, G. Anderson, Jian Shi, L. Ren, Xiao Zhao, Guangjun Nie   +14 more
semanticscholar   +1 more source

The Expression Levels and Concentrations of PD-1 and PD-L1 Proteins in Septic Patients: A Systematic Review

Diagnostics, 2022
Sepsis is a series of life-threatening organ dysfunction caused by an impaired host response to infection. A large number of molecular studies of sepsis have revealed complex interactions between infectious agents and hosts that result in heterogeneous ...
Mutiara Indah Sari, Syafruddin Ilyas
doaj   +1 more source

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Journal of Clinical Oncology, 2010
Purpose Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and tolerability of anti–PD-1 blockade in patients with treatment-refractory ...
J. Brahmer, C. Drake, I. Wollner, J. Powderly, J. Picus, W. Sharfman, E. Stankevich, A. Pons, Theresa M Salay, T. McMiller, Marta M. Gilson, Changyu Wang, M. Selby, J. Taube, R. Anders, Lieping Chen, A. Korman, D. Pardoll, I. Lowy, S. Topalian   +19 more
semanticscholar   +1 more source

Targeting Programmed Death 1/Programmed Death Ligand 1 in Lymphoma: A Game Changer [PDF]

Journal of Oncology Practice, 2016
Programmeddeath 1 (PD-1)/programmed death ligand 1 (PD-L1) engagement is a physiologic process that inhibits the overactivation of T cells and thus serves to maintain self-tolerance and prevent autoimmunity. This mechanism is frequently hijacked by tumor cells, including lymphoma, when they aberrantly express PD-L1 (and PD-L2) proteins; however, this ...
openaire   +2 more sources

Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1

Biomedicine & Pharmacotherapy, 2020
Rapidly increasing usages of immune checkpoint therapy for cancer treatment, particularly monoclonal antibodies that target programmed cell death-1 (PD-1) and its ligand PD-L1, have been achieved due to startling durable therapeutic efficacy with limited toxicity.
Jingjing, Fan, Xiangfeng, Shen, Yishu, Wang, Hong-Lan, Zhou, Guolong, Liu, Yu-Lin, Li, Zhi-Xiang, Xu   +6 more
openaire   +2 more sources

Programmed cell death protein 1 and programmed death ligand 1 expression in neuroendocrine carcinomas of the urinary bladder

Polish Journal of Pathology, 2021
Neuroendocrine carcinomas (NECs) of the urinary bladder are rare and aggressive, without an effective treatment approach. Immune checkpoint inhibitor agents targeting the interaction of programmed cell death protein 1 (PD-1) and programmed death ligand 1
Arbil Acikalin, Emine Bagir, Merve Inceman, Mutlu Deger, Seyda Erdogan   +4 more
doaj   +1 more source

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors [PDF]

, 2016
PURPOSE: Subsets of pituitary tumors exhibit an aggressive clinical courses and recur despite surgery, radiation, and chemotherapy. Because modulation of the immune response through inhibition of T-cell checkpoints has led to durable clinical responses ...
Agar, Nathalie Y. R., Bi, Wenya Linda, Du, Ziming, Dunn, Gavin P, Dunn, Ian F, Fecci, Peter E, Freeman, Gordon J, Greenwald, Noah F, Kaiser, Ursula B, Laws, Edward R, Jr, Mei, Yu, Reardon, David A, Santagata, Sandro, Woodmansee, Whitney W   +13 more
core   +3 more sources

Progress of Research on Programmed Death-1/Programmed Death Ligand-1 Inhibitors for HIV/AIDS with Cancer

Zhongliu Fangzhi Yanjiu, 2023
Immunotherapy has become a common means of cancer treatment. In immunotherapy, PD-1/PD-L1 inhibitors have significant efficacy. Cancer and various opportunistic infections are common complications in patients with AIDS.
DENG Changgang, ZHANG Wei, SUN Yanyu, LI Qisui, HUANG Wei, YUAN Jing   +5 more
doaj   +1 more source

Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent

OncoTarget, 2017
In order to explore the potential of immune checkpoint blockade in sarcoma, we investigated expression and clinical relevance of programmed cell death-1 (PD-1), programmed death ligand-1 (PD-L1) and CD8 in tumors of 208 sarcoma patients.
A. V. van Erp, Y. Versleijen-Jonkers, M. Hillebrandt-Roeffen, Laurens van Houdt, M. Gorris, Laura S. van Dam, T. Mentzel, M. Weidema, C. D. Savci-Heijink, I. Desar, H. Merks, Max M. van Noesel, J. Shipley, W. V. D. van der Graaf, U. Flucke, F. Meyer-Wentrup   +15 more
semanticscholar   +1 more source